A high level of T cell apoptosis was observed upon co-cultivation with PD-L1 expressing tumor cells, and T cell apoptosis was blocked by addition of an anti-PD1 antibody or gefitinib, suggesting that combining targeted TKI therapy with CAR-T cells may increase the persistence of CAR-T cells (81). Here, PDCD1 is linked to neoplasm.